Table 3 Clinical performance indicators by age groups

Percentage of new cases of invasive CMM assessed for neoplastic ulcer

≥ 90

94.87 (93.07–96.31)

91.42 (88.27–93.95)

90.61 (85.39–94.43)

0.024

0.085

0.089

0.870

1,368

100.00

CMM-TNM stage I–IIA (%) undergoing head CT scans, chest CT/MRI scans, abdominal CT/MRI scans, or PET scans within 180 days after diagnosis

< 10

3.03 (1.81–4.75)

3.82 (1.85–6.91)

3.45 (0.72–9.75)

0.779

-

-

-

943

68.93

Percentage of patients with 1-4-mm thick lesions

undergoing sentinel lymph node biopsy (SLNB)

≥ 90

94.16 (89.20-97.29)

81.63 (72.53–88.74)

60.00 (45.18–73.59)

< 0.001

0.007

< 0.001

0.008

1,066

77.92

Percentage of patients with lesions < 0.8 mm in thickness and no reported ulceration or mitoses undergoing SLNB

< 10

4.43 (2.44–7.32)

3.76 (1.23–8.56)

2.44 (0.06–12.86)

1.000

-

-

-

490

35.82

Percentage of patients with time elapsing between biopsy and complete excision < 60 days

≥ 90

62.27 (58.62–65.83)

59.77 (54.45–64.93)

58.47 (49.04–67.47)

0.600

-

-

-

1,192

87.13

Percentage of cases with pT1-T2 disease ≤ 2.0 mm in thickness and surgical margins < 0.8 cm

< 10

31.74 (27.99–35.68)

26.07 (20.57–32.19)

32.84 (21.85–45.40)

0.251

-

-

-

887

66.59

Percentage of cases with pT1, pT2 disease ≤ 2.0 mm in thickness and surgical margins > 1.2 cm

No-TH

24.23 (20.81–27.91)

30.34 (24.52–36.67)

38.81 (27.13–51.50)

0.015

0.173

0.044

0.247

887

66.59

Percentage of cases with pT3, pT4 disease 2.0 mm in thickness and surgical margins < 1.6 cm

< 10

57.50 (45.94–69.78)

59.30 (48.17–69.78)

69.57 (54.25–82.26)

0.381

-

-

-

212

15.69

Percentage of cases with pT3, pT4 disease > 2.0 mm in thickness and surgical margins > 2.4 cm

No-TH

3.75 (0.78–10.57)

6.98 (2.60-14.57)

4.35 (0.53–14.84)

0.727

-

-

-

212

15.69

Percentage of SLNB-positive patients

≥ 15

18.01 (14.18–22.37)

18.85 (13.56–25.13)

16.36 (7.77–28.80)

0.911

-

-

-

607

44.37

Percentage of SLNB-positive patients undergoing

lymphadenectomy

No-TH

85.45 (73.34–93.50)

84.38 (67.21–94.72)

44.44 (13.70–78.80)

0.024

1.000

0.039

0.051

96

7.02

Percentage of patients undergoing SLNB in a regional reference center

≥ 90

62.88 (57.67–67.88)

59.38 (52.07–66.39)

50.00 (35.81–64.19)

0.187

-

-

-

605

44.23

Percentage of TNM stage IB–III patients undergoing nodal US within 12 months of wide excision

≥ 95

61.69 (56.41–66.77)

62.38 (55.31–69.08)

38.64 (28.44–49.62)

< 0.001

0.945

< 0.001

< 0.001

645

48.24